studies have reported on the combination of the 4 Ts score with an immunoassay (enzyme immunoassay [EIA], particle gel immunoassay [PaGIA] ) in improving the likelihood of attaining a correct diagnosis.
2,12,16
More recently, a new scoring system for HIT based on a consensus of expert opinion, the HIT Expert Probability (HEP) score, was devised.
14 Scoring is based on eight clinical features thought to be clinically significant in HIT (including magnitude and timing of fall in platelet count, nadir platelet count, occurrence of thrombosis, skin necrosis and acute systemic reactions, bleeding, and presence of other causes of thrombocytopenia). While the study population was small, the HEP score showed greater interobserver agreement, superior specificity, and better correlation with HIT laboratory testing than the 4 Ts score. Furthermore, the HEP score would have resulted in a 41% reduction in use of a direct thrombin inhibitor had it been integrated into clinical decision-making. However, it is a more complex scoring system than the 4 Ts and hence its implementation may be challenging, especially in smaller institutions. Accurate clinical scoring for HIT can be difficult, particularly in regional hospitals and in critical care settings where hemodilution, increased platelet destruction, and increased platelet consumption (trauma, bleeding, disseminated intravascular coagulation [DIC] ) are far more common causes of thrombocytopenia. 4, 6, 17 Thus, laboratory screening tests such as immunoassays are crucial in HIT diagnosis.
7,18-21

ANTI H-PF4 Antibody Detection Assays
Immunoassays detect antibodies which bind to platelet factor (PF) 4/polyanion complexes and were first described by Amiral and colleagues in 1992. 22 Immunoassays can detect the presence of H-PF4 antibodies, but not their ability to activate platelets and trigger clinical HIT. Hence immunoassays have high sensitivity and are useful screening tools for HIT, but lack specificity, with a high rate of false positives. 9, 18, 20, [23] [24] [25] Antigen-based immunoassays that are widely used in HIT diagnosis fall into two main groups: Solid-phase EIAs 22 and PaGIAs.
1
PaGIAs
A type of immunoassay that is used as a screening test for HIT are the PaGIAs, particularly the ID-HPF4 PaGIA (Diamed AG, Cressier sur Morat, Switzerland). 9, [26] [27] [28] This method uses gel centrifugation technology that is similar to that typically incorporated into blood bank serological investigations. Red high-density polystyrene beads are coated with H-PF4 complexes and will form aggregates in the presence of a secondary anti-human immunoglobulin antibody if anti H-PF4 antibodies are present. The PaGIA is a qualitative assay and is technically simple to perform, and has the significant advantage of rapid turnaround time, with results available in under an hour. Agreement between results in plasma and serum samples and between fresh and frozen/thawed samples seems excellent.
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The utility of the PaGIA was enhanced when combined with the 4 Ts score. 12, 16 In the same study by Pouplard et al, the probability of HIT in intermediate risk patients based solely on the 4 Ts score was reduced from 10.9 to 0.6% when combined with a negative PaGIA result. Hence the combination of a 4 Ts score and PaGIA appears to be a suitable strategy to rule out HIT. The PaGIA would appear to have high utility in peripheral laboratories. However, the issue of false-negative results is critically important for assessing a screening test, and several prospective studies have assessed the performance of the PaGIA. In the study by Bakchoul et al, the PaGIA had a lower PPV (37 vs Evaluating Heparin-Induced Thrombocytopenia Tan et al.
EIAs are technically simple to perform, and can be easily integrated into automated platforms in routine laboratories, measuring large numbers of samples simultaneously. 9, 20, 28 EIAs are also highly sensitive, with sensitivities and NPV of 100% reported in various studies. 18, 31, 33 Bakchoul et al reported superior specificity of the IgG-specific EIA to the polyspecific EIA with identical sensitivity (100%). , without significantly altering the sensitivity. 31 Pouplard et al reported a specificity of 90% for the Zymutest HIA IgG compared with 77% in the corresponding polyspecific test. 41 IgG-specific assays were also superior to their polyspecific counterparts in a recent study by MorelKopp et al.
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High Optical Density (OD) Associated with Better PPV Despite these encouraging results, the PPV of IgG-specific assays in studies comparing such assays with functional tests such as the HIPA remain modest (40 to 55%) 33, 43 .
Another method of increasing the specificity of the IgGspecific assays is to raise the OD cutoffs for positive results. 18, 21, 23, 25, 33, 34, 38, 43, 44 Current manufacturer's cutoffs for the three main EIAs range from 0.4 to 0.5. Zwicker et al reported that mean EIA OD measurements were significantly higher in HIT patients with thrombosis, and patients with an initial OD reading of >1.0 had a sixfold increase in risk of future thrombotic events compared with patients with OD results between 0.4 and 0.99. 44 Lo et al reported good correlation of strong EIA-GTI reactivity (>1.20 OD) with positivity for SRA and intermediate or high clinical pretest probability for HIT. 24 Warkentin et al calculated the likelihood of a pathogenic HIT antibody based on SRA results being greater than 50% with an OD result 1.40 units.
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Higher OD values also correlated well with clinical outcomes of HIT in another study. 33 There is increasing acceptance that the higher the OD value, the greater the likelihood of clinical HIT for a given pretest probability. Efforts to standardize the reporting of OD results for EIA in ranges to predict likelihood of pathogenic HIT antibodies have commenced.
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High-Dose Heparin Confirmatory
Step May Improve EIA Specificity
The addition of a confirmatory step using high-dose heparin may also improve the utility of EIAs. Whitlatch et al performed an extra confirmatory step by adding high-dose heparin (100 IU/mL) to samples which were EIA (GTI) positive and compared outcomes with assessment of HIT as per the clinical criteria outlined by the American College of Chest Physicians guidelines 38 ; 98% of EIA-positive samples were also confirmatory test positive. Importantly, patients who were positive for the confirmatory test were more likely to be diagnosed with clinical HIT than patients who were negative (72 vs. 18%, p < 0.001). A further study by the same authors also emphasized the utility of the confirmatory test.
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However, in another study of cardiac surgery patients, the confirmatory step did not improve diagnostic specificity of the EIA. 46 A further study, also in the cardiac surgery setting, showed that only 50% of HIPA-positive samples were positive for the EIA confirmatory test. 47 In the same study, one of three patients who unequivocally satisfied clinical criteria for HIT was negative for the confirmatory test. In another study, the additional confirmatory step improved specificity at the expense of sensitivity. 33 More recently, Althaus et al reported that use of high-dose heparin (100 IU/mL) increased the specificity of EIAs with weak OD (0.5 to 1.0 units) but not strong OD (1.0 units) results, with a significant risk of false negatives (16%) associated with testing of strongly positive ODs. 48 It is also possible that the confirmatory test can inhibit true pathogenic antibodies and hence not add further information to the onestep EIA. 7 More prospective information is needed to confirm the utility of the confirmatory step, and also whether its utility varies according to the clinical setting. Despite IgG-specific assays and higher diagnostic cutoffs for OD, the specificity of EIAs remains modest at best. If diagnosis is based solely on a positive EIA result, 50% of patients will be mislabeled as being positive for HIT, with attendant bleeding risks associated with the use of nonheparin anticoagulants. 24, 43 It has been suggested that the OD for the EIA be further raised to 2.0 in the surgical intensive care unit setting to improve its utility. 15 Hence functional assays, which detect the presence of pathogenic antibodies by their ability to induce platelet activation and have high specificity, continue to play a major role in the diagnosis of HIT.
Functional Assays
The two most widely used functional assays are the SRA and the HIPA test. 49 The SRA has been reported to be the most sensitive and specific of the functional assays. 20 In this assay, donor platelets are washed and incubated with 14 C-labeled serotonin. In the presence of platelet activating H-PF4 antibodies, serotonin is released from the dense granules of platelets and test results are positive if there is >20% release at therapeutic heparin levels (0.1 to 0.3 IU/mL) and <20% release at supratherapeutic heparin levels (10 to 100 IU/mL). 49 The utility of the assay is enhanced by (1) the selection of suitable platelet donors, (2) the use of apyrase, an adenosine diphosphate scavenger, in the washing step, (3) additional testing involving the usage of a FCγRIIa monoclonal antibody directed against the FCγRIIa receptor (which suppresses the reactivity of HIT-positive serum), 68 and (4) the addition of low-molecular-weight heparin (LMWH), which may give better reactivity for weak samples (Warkentin TD, personal communication, ISTH Kyoto 2011). However, the SRA includes radioactive isotopes, is laborand time-intensive, and requires specialized personnel and equipment, thus limiting its use to major reference laboratories. 9, 20 The SRA is performed very infrequently in Australia, with results only available retrospectively. Hence the value of the SRA on decision-making in the acute setting is limited, although this may be a lesser issue in countries with established referral laboratories (i.e., United States and Canada).
Donor Selection
HIPA Assay
The HIPA test, first described by Greinacher et al in 1991, is the most widely used functional assay in Europe and obviates the need for radioisotope tracers. 50 Washed platelets prepared from citrated blood obtained from four random healthy donors (reactivity to HIT-positive plasma is unknown) are incubated with both therapeutic heparin (0.1 to 1.0 IU/mL) and supratherapeutic heparin (100 IU/mL) and patient serum, with buffers acting as negative controls. 7, 69 A positive test is demonstrated with transparency of the suspension (visual evaluation) at therapeutic but not high-dose heparin in at least two of the four healthy donors. The HIPA has similar sensitivity and specificity to the SRA, and has the advantages of a more rapid turnaround time of results compared with the SRA (results reported within 24 hours in Germany) without the use of radioactivity.
35 However, it remains technically challenging, particularly in peripheral laboratories, and is not amenable to automation, unlike the EIAs. Furthermore, there is a possibility that the PRP of all four healthy donors used in HIPA testing do not react well to HIT antibodies (low responders), raising the possibility of false negatives.
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Whole Blood Impedance Aggregometry (WBIA)
Concerns regarding the preanalytical and analytical variables that can impact on the utility of LTA have lead to the development of WBIA. Originally designed to monitor the effectiveness of antiplatelet therapy, WBIA can now be used to assist in the diagnosis of HIT. 59, 70 The Multiplate ® analyser (Verum Diagnostica, Munich, Germany) is one such instrument, in which platelet aggregation as a result of the presence of pathogenic H-PF4 antibodies is detected as an increase in impedance across paired electrodes. The advantages of the WBIA include a rapid turnaround time, and it is easy to perform. As it is a whole blood assay, there is no requirement for sample manipulation to generate PRP, platelet-poor plasma, or washed platelets, minimizing artifactual platelet activation. Morel-Kopp et al reported on the efficacy of WBIA in diagnosing HIT using a known reactive platelet donor, with superior sensitivity to LTA, and comparable results to SRA.
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Other Functional Assays
Flow Cytometry
Functional assays using the capabilities of flow cytometry have also been developed. Khairy et al described a whole blood flow cytometry assay measuring the presence of leucocyte-platelet aggregates (defined as events positive for both the presence of CD45 and platelet glycoprotein IIb) as a marker of platelet activation with different heparin concentrations, using plasma from HIT-positive patients. Evaluating Heparin-Induced Thrombocytopenia Tan et al.
Leucocyte-platelet aggregates were found in 75% of HITpositive patients, and correlated with levels of anti H-PF4 antibodies as determined by EIA. The advantages of this assay are the option of analyzing the sample up to 24 hours from collection with usage of the fixative, paraformaldehyde, and the usage of whole blood, hence requiring lesser volumes. Platelet microparticles are thought to contribute to the procoagulant effects of HIT-positive sera and the use of flow cytometry to measure HIT antibody-induced microparticle generation was first described by Warkentin and colleagues. 72 More recently, Mullier et al reported on a pilot study examining the utility of a flow cytometry-based platelet microparticle generation assay as a marker of platelet activation in HIT. 73 Platelet microparticles ranged in size from 0.5 to 1.0 µm, and were also defined by the expression of platelet glycoprotein Ib, CD41, and annexin V in this assay. While this was a pilot study, the assay showed good correlation with the SRA (specificity, 0.96; NPV, 1) and also reversal of reactivity with high-dose heparin (500 IU/mL) compared with the therapeutic dose (1 IU/mL). A flow cytometry-based functional assay measuring CD62 was first described by Jy et al 74 and later modified by Denys and colleagues.
2 It has been reported that CD62 is a more reliable marker of platelet activation as a result of the presence of pathogenic H-PF4 antibodies than the procoagulant phospholipid annexin V.
75,76
Thrombin Generation
Tardy-Poncet et al measured thrombin generation in PRP as a marker of the hypercoagulable state induced by HIT as a result of generation of procoagulant platelet microparticles. 61 The resultant calibrated automated thrombogram (CAT) with or without heparin was then compared between HIT positive and HIT negative patients. While the above results of newer functional assays appear promising, more prospective studies are required to validate these tests. Furthermore, these assays are currently limited to research laboratories. Assays which measure thrombin generation may have uncertain specificity as other causes of thrombocytopenia in patients suspected of HIT can also reflect hypercoagulable states, such as DIC and sepsis.
61
Some publications have shown that H-PF4 antibodies are able to activate platelets in the absence of heparin during SRA and HIPA testing. 77, 78 The spontaneous platelet activation observed was not eliminated by the addition of heparinase or via chromatography in both functional assays. Hence, the immune response of HIT is similar to that of an autoimmune process and may explain the clinical manifestations of delayed-onset HIT. While such antibodies are unlikely to affect the results of the SRA or HIPA (as these assays do not always include a no-heparin step), they may influence the utility of the newer assays such as the measurement of thrombin generation via the CAT where baseline thrombin generation is already maximal due to the platelet-activating properties of such antibodies independent of heparin.
Conclusions
HIT is a clinicopathological syndrome and hence both clinical and laboratory assessments are essential for accurate diagnosis. A wide range of immunoassays and functional tests are now available (►Table 1). In a recent report on the clinical and laboratory management of suspected HIT in current practice, the authors commented about the lack of clinical information provided to laboratories performing HIT testing. 19 The authors commented that use of UFH at therapeutic doses and the presence of thrombosis appear to be excellent predictors of HIT. This is supported by the fact that in a recent metaanalysis, the absolute risk of HIT associated with use of LMWH at prophylactic doses was very low (0.2%). 79 Hence, It is imperative that cooperation between clinicians and laboratories exists to ensure relaying of relevant clinical data to aid laboratory diagnosis. Such clinical information may be conveyed in the form of a validated scoring system, such as the 4 Ts.
11 While the 4 Ts score has a high NPV, reporting varies between centers and may be more difficult in medical and critical care settings. 6, 13, 15, 23 A new score, the HEP score may correlate better The biggest drawback of the EIAs is that its PPV remains modest. EIAs are therefore useful in ruling out, but not in confirming HIT. Hence, functional assays, which have high specificity, play an important role in the assessment of HIT. We recommend that the combination of a clinical score such as the 4 T and an immunoassay be used as initial screening for HIT, with results guiding further testing by a functional assay as outlined in ►Fig. 1. The clinician may consider omitting further testing in samples with low 4 Ts score. Functional testing (SRA, HIPA, or WBIA) is recommended as a confirmatory test for positive EIA results with equivocal or strong ODs, and should occur after cessation of heparin.
Functional assays are technically demanding to perform, and are less practical to assist clinical decision-making in the acute setting. However, new methods are emerging that may address this issue. Data regarding the use of WBIA appear promising, and various flow cytometry assays measuring a range of markers of platelet activation have the advantages of rapid turnaround time, require less sample volume and show good correlation with other functional assays in initial studies. Future prospective studies validating such methods are awaited.
In summary, accurate HIT diagnosis requires clinical judgment and a sensitive screening test initially, followed by a functional assay to confirm suspected HIT.
In North America, samples are referred to major reference laboratories for SRA for confirmatory testing, with results available within 1 or 2 days. Similarly, in Germany, a network of laboratories with capability of performing the HIPA has been established, enabling nationwide access to a functional assay, with results generally reported within 24 hours. This is a model which we believe should be adopted in any consensus approach to HIT diagnosis. In Australia, a large study was recently completed, with samples sent to a reference laboratory for functional testing by WBIA and SRA and results have confirmed the utility of the WBIA as an alternative functional assay for HIT. 
